

ZANDER

Serial No. Unknown

Mikroorganismen Und Zellkulturen GmbH, Mascheroder Weg 1b, D-38124 Braunschweig,
Germany, on March 27, 2000.


A marked-up copy of the amended claims is also attached.

An early and favorable Action on the merits is requested.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: _____



B. J. Sadoff
Reg. No. 36,663

BJS:ms

1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

MARKED-UP COPY OF AMENDED CLAIMS

3. (Amended) Vector according to Claim 1 [or 2], characterized in that the nucleic acid sequence codes for the surface marker is the sequence indicated in SEQ ID NO: 1, 3 or 5 or for a fragment, a mutant or variant of the same.
4. (Amended) Vector according to [Claims 1 to 3] Claim 1, characterized in that it is a retroviral vector.
5. (Amended) Vector according to [Claims 1 to 4] Claim 1, characterized in that it contains a nucleic acid sequence coding for a further surface marker.
9. (Amended) Host cell, characterized in that it is transduced with a vector according to [Claims 1 to 8] Claim 1.
12. (Amended) Method for the detection of genetically modified cells, characterized in that the cells are transduced with a vector according to [Claims 1 to 5] Claim 1 and the transduced cells are identified by detection of the surface marker.
13. (Amended) Method for the selection of genetically modified cells, characterized in that the cells are transduced with a vector according to [Claims 1 to 5] Claim 1, bound to an agent specific to the surface marker, and separated from the genetically unmodified cells.
16. (Amended) Method according to Claim 14 [or 15], characterized in that the nucleic acid sequence codes for a surface marker according to SEQ ID NO: 2, 4 or 6 or for a fragment or a variant of the same.
17. (Amended) Method according to Claims 14 [or 15], characterized in that the nucleic acid sequence coding for the surface marker is the sequence indicated in SEQ ID NO: 1, 3 or 5 or a fragment, mutant or variant of the same.
18. (Amended) Method according to [Claims 14 to 17] Claim 14, characterized in that the vector is a retroviral vector.

19. (Amended) Method according to [Claims 14 to 18] Claim 14, characterized in that the vector corresponding to DSM 13396 is used.

20. (Amended) Method according to [Claims 12 to 19] Claim 12, characterized in that the cells are human cells.

22. (Amended) Kit [for carrying out a method according to Claim 12, characterized in that it contains] containing a vector according to [Claims 1 to 5,] Claim 1 and means for the specific detection of [the] a surface marker, and further agents and aids required for carrying out [the] a detection.

23. (Amended) Kit [for carrying out a method according to Claim 14, characterized in that it contains] containing a vector [as mentioned in Claims 14 to 19] of Claim 14 and, means for the specific detection of [the] a surface marker and further agents and aids required for carrying out [the] a detection.

26. (Amended) Use of a vector according to [Claims 1 to 5] Claim 1 for *in vitro* transduction of T-lymphocytes.

27. (Amended) Use of a vector according to [Claims 1 to 5] Claim 1 for gene therapeutic treatment.

28. (Amended) Use of T-lymphocytes which are transduced with a vector according to [Claims 1 to 5] Claim 1, for gene therapeutic treatment.

31. (Amended) Gene therapeutic drug, containing a vector according to [Claims 1 to 5] Claim 1.

32. (Amended) Gene therapeutic drug, containing T-lymphocytes, which are transduced with a vector according to [Claims 1 to 5] Claim 1.